1/16
07:02 pm
gild
Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025-2031: Yescarta from Gilead Sciences and Zolgensma from Novartis Generated $1.5 Billion and $1.2 Billion in 2024 Sales [Yahoo! Finance]
Low
Report
Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025-2031: Yescarta from Gilead Sciences and Zolgensma from Novartis Generated $1.5 Billion and $1.2 Billion in 2024 Sales [Yahoo! Finance]
1/15
05:08 pm
gild
Gilead Sciences (NASDAQ:GILD) had its price target lowered by analysts at Royal Bank Of Canada from $105.00 to $100.00. They now have a "sector perform" rating on the stock.
Medium
Report
Gilead Sciences (NASDAQ:GILD) had its price target lowered by analysts at Royal Bank Of Canada from $105.00 to $100.00. They now have a "sector perform" rating on the stock.
1/15
05:08 pm
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $110.00 to $115.00. They now have a "neutral" rating on the stock.
Medium
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $110.00 to $115.00. They now have a "neutral" rating on the stock.
1/15
03:59 pm
gild
Hopping Mad Over Drug Company Product Hopping [Forbes]
Neutral
Report
Hopping Mad Over Drug Company Product Hopping [Forbes]
1/15
01:03 pm
gild
Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
1/15
11:16 am
gild
Genetic Modification Therapies Set to Surge, Market Valued at $32.1 Billion by 2030 [Yahoo! Finance]
Low
Report
Genetic Modification Therapies Set to Surge, Market Valued at $32.1 Billion by 2030 [Yahoo! Finance]
1/13
11:28 am
gild
Gilead Sciences (NASDAQ:GILD) had its price target lowered by analysts at Morgan Stanley from $151.00 to $150.00. They now have an "overweight" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target lowered by analysts at Morgan Stanley from $151.00 to $150.00. They now have an "overweight" rating on the stock.
1/13
10:59 am
gild
Gilead Sciences (NASDAQ:GILD) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
1/12
06:13 pm
gild
Gilead Sciences: From All-Time Highs To Higher Highs [Seeking Alpha]
Low
Report
Gilead Sciences: From All-Time Highs To Higher Highs [Seeking Alpha]
1/12
04:45 am
gild
UBS and Citi Go Bullish on Gilead Sciences (GILD) [Yahoo! Finance]
Low
Report
UBS and Citi Go Bullish on Gilead Sciences (GILD) [Yahoo! Finance]
1/11
11:51 pm
gild
The Bull Case For Gilead Sciences (GILD) Could Change Following New OncoNano Drug-Delivery Collaboration [Yahoo! Finance]
Low
Report
The Bull Case For Gilead Sciences (GILD) Could Change Following New OncoNano Drug-Delivery Collaboration [Yahoo! Finance]
1/11
11:41 am
gild
Is Gilead Sciences (GILD) Pricing Reflecting Recent 38.5% One Year Share Return? [Yahoo! Finance]
Low
Report
Is Gilead Sciences (GILD) Pricing Reflecting Recent 38.5% One Year Share Return? [Yahoo! Finance]
1/10
09:33 am
gild
Gilead price target raised to $154 from $144 at BofA [Yahoo! Finance]
Low
Report
Gilead price target raised to $154 from $144 at BofA [Yahoo! Finance]
1/9
07:03 pm
gild
J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts [Yahoo! Finance]
Low
Report
J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts [Yahoo! Finance]
1/8
04:25 pm
gild
Patient advocacy groups urge U.S. court to halt overseas prescription drug operations [CNBC]
Low
Report
Patient advocacy groups urge U.S. court to halt overseas prescription drug operations [CNBC]
1/7
02:55 pm
gild
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Citigroup Inc. from $135.00 to $140.00. They now have a "buy" rating on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Citigroup Inc. from $135.00 to $140.00. They now have a "buy" rating on the stock.
1/7
11:27 am
gild
RAAP: Alternative Funding Programs Put Rare Patients in Jeopardy [Yahoo! Finance]
Low
Report
RAAP: Alternative Funding Programs Put Rare Patients in Jeopardy [Yahoo! Finance]
1/7
08:55 am
gild
Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at UBS Group AG. They now have a $145.00 price target on the stock, up previously from $112.00.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at UBS Group AG. They now have a $145.00 price target on the stock, up previously from $112.00.
1/7
04:26 am
gild
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Momentum [Yahoo! Finance]
Low
Report
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Momentum [Yahoo! Finance]
1/6
07:00 am
gild
OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate
Low
Report
OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate
1/3
01:06 am
gild
Gilead Sciences (NASDAQ:GILD) was upgraded by analysts at
Wall Street Ze
Low
Report
Gilead Sciences (NASDAQ:GILD) was upgraded by analysts at
Wall Street Ze
12/31
06:17 am
gild
Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs [Yahoo! Finance]
Low
Report
Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs [Yahoo! Finance]
12/30
07:27 pm
gild
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today [Yahoo! Finance]
Low
Report
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today [Yahoo! Finance]
12/30
12:17 am
gild
Is Gilead Sciences (GILD) An Affordable Healthcare Stocks to Invest In? [Yahoo! Finance]
Low
Report
Is Gilead Sciences (GILD) An Affordable Healthcare Stocks to Invest In? [Yahoo! Finance]
12/29
10:14 am
gild
Gilead Sciences (NASDAQ:GILD) was given a new $135.00 price target on by analysts at Sanford C. Bernstein.
Low
Report
Gilead Sciences (NASDAQ:GILD) was given a new $135.00 price target on by analysts at Sanford C. Bernstein.